ELSEVIER

Contents lists available at ScienceDirect

## **Antiviral Research**

journal homepage: www.elsevier.com/locate/antiviral



## Corrigendum to "Experience with intravenous ribavirin in the treatment of hemorrhagic fever with renal syndrome in Korea"

Janice M. Rusnak<sup>a,\*</sup>, William R. Byrne<sup>a</sup>, Kyung N. Chung<sup>b</sup>, Paul H. Gibbs<sup>c</sup>, Theodore T. Kim<sup>b</sup>, Ellen F. Boudreau<sup>a</sup>, Thomas Cosgriff<sup>a</sup>, Philip Pittman<sup>a</sup>, Katie Y. Kim<sup>d</sup>, Marianne S. Erlichman<sup>e</sup>, David F. Rezvani<sup>f</sup>, John W. Huggins<sup>g</sup>

- <sup>a</sup> Division of Medicine, U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), United States
- <sup>b</sup> Department of Internal Medicine, 121st General Hospital, Seoul, South Korea
- <sup>c</sup> Research Support Statistics, USAMRIID, ,United States
- <sup>d</sup> Department of Pharmacy, 121st General Hospital, Seoul, South Korea
- <sup>e</sup> Force Health Protection, United States Army Medical Material Development Activity, ,United States
- <sup>f</sup> Information Services Office Division, USAMRIID, ,United States
- g Division of Virology, USAMRIID, United States

The authors regret that in the original printing of the above-mentioned paper, the legends for Figs. 4 and 5 were produced incorrectly. The figures complete with correct legends are reproduced below.

The authors would like to apologise for any inconvenience this may have caused to readers of the journal.




Fig. 4. Mean platelet count (by day of IV ribavirin therapy) in the IV ribavirin treatment analysis cohort of 34 individuals.

DOI of original article: 10.1016/j.antiviral.2008.09.007.

<sup>\*</sup> Corresponding author at: 1425 Porter Street, Division of Medicine, U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, United States. Tel.: +1 301 619 4156; fax: +1 301 619 2511.




Fig. 5. Time of occurrence of the nadir platelet count (by day of IV ribavirin therapy) in the IV ribavirin treatment analysis cohort of 34 individuals.